logo

FDA Calendar

Share
Company Name GlaxoSmithKline PLC
Drug Name Belantamab mafodotin (BLA)
Event Name FDA decision on Belantamab mafodotin for the treatment of patients with relapsed or refractory multiple myeloma
Event Date 06/19/2020
Outcome Date
Outcome
Drug Status Priority review
Rival Drugs
Market Potential
Other Approvals
News
Return to FDA Calendar

>